12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Nucynta tapentadol ER regulatory update

FDA approved an sNDA from Johnson & Johnson's Janssen Pharmaceuticals Inc. subsidiary for Nucynta tapentadol extended-release (ER) tablets to manage neuropathic pain associated with diabetic peripheral neuropathy...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >